Table 1.
Characteristics of depression, suicidal ideation and behavior, and all adverse drug reactions reported for the monoclonal antibodies
| Depression ADRs (%) | Suicidal ideation and behavior ADRs (%) | |
|---|---|---|
| Total (n = 2,924,319) | 9455 (0.32) | 1770 (0.06) |
| Sex | ||
| Male (n = 889,618) | 2423 (0.27) | 638 (0.07) |
| Female (n = 1,896,884) | 6669 (0.35) | 1072 (0.06) |
| Unknown (n = 137,817) | 363 (0.26) | 60 (0.04) |
| Age, years | ||
| < 18 (n = 62,164) | 97 (0.16) | 61 (0.10) |
| 18–44 (n = 516,973) | 1830 (0.35) | 515 (0.10) |
| 45–64 (n = 838,942) | 2822 (0.34) | 525 (0.06) |
| ≥ 65 years (n = 481,932) | 868 (0.18) | 98 (0.02) |
| Unknown (n = 1,024,308) | 3838 (0.37) | 571 (0.06) |
| Region | ||
| Africa (n = 3438) | 7 (0.20) | 1 (0.03) |
| The Americas (n = 2,433,422) | 8648 (0.36) | 1523 (0.06) |
| Southeast Asia (n = 4372) | 2 (0.05) | 3 (0.07) |
| Europe (n = 376,078) | 640 (0.17) | 196 (0.05) |
| Eastern Mediterranean (n = 3252) | 5 (0.15) | 1 (0.03) |
| Western Pacific (n = 103,757) | 153 (0.15) | 46 (0.04) |
| Reporting years | ||
| 1995–1999 (n = 1367) | 0 (0) | 0 (0) |
| 2000–2004 (n = 52,267) | 57 (0.11) | 5 (0.01) |
| 2005–2009 (n = 284,580) | 659 (0.23) | 183 (0.06) |
| 2010–2014 (n = 1,243,659) | 4928 (0.40) | 782 (0.06) |
| 2015–2017 (n = 1,342,446) | 3811 (0.28) | 800 (0.06) |
| Reporter | ||
| Healthcare professional (n = 1,413,828) | 3221 (0.23) | 991 (0.07) |
| Consumer (n = 1,285,732) | 5600 (0.44) | 633 (0.05) |
| Other (n = 29,983) | 110 (0.37) | 32 (0.11) |
| Unknown (n = 194,776) | 524 (0.27) | 114 (0.06) |
ADRs adverse drug reactions